A private investment group based in Canada is looking to make growth stage investments in medical device companies. The firm does not manage a committed fund of capital. The firm’s partners generally make up 20-25% of the capital and raises additional capital on a deal-by-deal basis from a small group of high net worth investors. The firm invests in companies that are based in North America. The firm is actively looking for new investment opportunities. 

In the Life Sciences the firm is currently seeking to invest in medical devices with market approval. The firm is opportunistic in terms of the class and indications. Historically, the firm invested in an image guided medical laser technology although they are open to all recently approved devices.

ECP seeks to be an active investor and will require a board seat/observer rights. The firm only invests in commercial stage companies but the firm does not have revenue requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canadian government-funded firm is currently investing out of a healthcare fund targeting series A rounds, but it is open to other rounds. The firm seeks to allocate 10-15 million CAD over the life of an investment. The firm only invests in Canadian companies and is currently seeking new investment opportunities.

In the life sciences, the firm seeks to invest in therapeutics, diagnostics, medical devices, and HCIT. The firm is opportunistic in terms of stage of development and indications. For therapeutics, the firm prefers products that are at least beginning its Phase I trials and is open to orphan indications. For medical devices, the firm prefers companies with a working prototype. 

The firm generally seeks Board of Directors representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that is based in the Eastern United States is looking to make equity investments into early stage companies of under $1 million generally in the Seed or Series A Round. The firm is also very open to syndication with other investors for larger rounds. The firm is looking for companies throughout the United States and is actively seeking new investment opportunities.                 

Within the life science space the firm is interested in companies that are leveraging advanced materials science in sub sectors of bio materials, diagnostics, analytics, and life science tools/services. Current portfolio companies in the space include companies developing improved therapeutics via biophysical and surface engineering, instruments and consumables for genetic analysis, DNA directed synthesis applied to human therapeutics and clinical diagnostics, and specialty enzymes for medical, biofuel, and industrial applications.

The firm is looking for privately held companies with experienced management teams. The firm looks to play an active role in its portfolio companies and generally looks to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A social impact investment fund with offices in Europe and the United States fund was launched with a total of $108 million in capital to invest into companies that are improving the quality of lives in low-income countries through the eradication of preventable diseases. The firm looks to allocate anywhere from $3+ million into companies with the ability to allocate up to $15 million over the lifetime of the investment. The firm primarily looks to provide mezzanine debt financing although they can be very flexible in terms of capital structure. The firm is actively reviewing opportunities and is open to invest in companies from around the globe.

The firm is currently looking for companies developing therapeutics, diagnostics, and medical devices. The firm is looking for companies targeting the full spectrum of global diseases including cholera, diarrhea, HIV, malaria, and TB, as well as products for improving global nutrition, maternal health and family planning. The firm is looking for companies that have POC data in humans and require financing to complete their trials, gain country regulatory approval and begin commercialization.

The firm is looking for private or public companies with an experienced management team. The firm looks to take a board/observer seat on a case by case basis in companies where they can add strategic value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office with offices in the Northeast and Midwestern United Sates invests its principal capital into high growth companies in both the private and public sectors. The firm’s investment size is highly variable and dependent on the financial needs of the company. The firm often leads investment rounds and also has the ability to leverage its additional network of high-net worth families and like-mined co investors to syndicate for larger deals as well as follow on investments.  The firm looks to invest in companies throughout the United States and has no set number of investments in plans to make, however they are actively reviewing new opportunities.

Within healthcare, the firm is most interested in companies developing devices and diagnostics. The firm is looking for companies devices that solve a significant medical problem with strong IP. The firm is willing to invest in companies from the prototype stage to those that already have their product on the market and is generally agnostic in terms of indication. Historically the firm has invested in companies working with cardiac devices and also has held special interest in the pediatrics space. The firm is generally not as interested in consumer facing devices. The firm is also willing to consider investments in the Therapeutics space though this area is less of a focus.

The firm is looking for companies that have experienced management teams and a strong board behind them. The firm is willing to invest in both privately and public held companies, with special interested in making PIPE investments. The firm looks to take a board seat into companies on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm is looking to make direct equity investments into life science companies ranging from $5-25m, primarily in the USA and Europe, with the potential to invest in other areas if the right syndication opportunities are available.  The firm typically makes 10 new direct investments per year across a diverse range of sectors, including healthcare IT, therapeutics and medical devices.  The firm leads or co-leads financing rounds in about 60% of cases and takes a board seat in these instances, but on other occasions may syndicate with other investors and not take a board seat.

The firm prefers to invest in medical devices and therapeutics with the potential to become the standard of care in a large clinical area with unmet needs.  Focus indications include oncology, immunology, cardiology, diabetes, neurology, infectious diseases, respiratory disorders, pain management and psychiatry.  The firm prefers to invest in the later clinical stages (Phase II + III), but will consider opportunistic investments in earlier stage opportunities if the firm sees the potential for outsized risk-adjusted returns due to a market dislocation.

The firm also invests in healthcare IT companies that have a product already on the market and have attained revenue and customer adoption.  These investments are in a variety of market segments, including enterprise software, clinical management software, connected devices/equipment and direct-to-consumer products.

In the therapeutic and medical device sectors, the firm seeks to invest in companies with unique intellectual property and with strong investor syndicates who can fund late-stage clinical trials to completion.  In the healthcare IT sector, the firm prefers to invest in companies with at least $5m in revenue and strong, experienced management teams.  The firm performs thorough due diligence, looking at factors such as historical performance, size of market opportunity, revenue per customer and customer stickiness in addition to vetting the product itself and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital fund of a large insurance provider is looking to make private investments in the healthcare space ranging from $5 – $15 million in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interested to its parent also seeking strong financial returns. The firm is willing to look at opportunities around the globe.

Within healthcare the firm is looking to invest in sectors of healthcare IT, services, and diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com